Dear [Name],

I hope all is well and sorry to disturb you again.

We just wanted to send a little reminder regarding the email below. We have one additional question:

- We have gathered that the selection of 10 therapeutics will be based on EMA’s current review of 57 potential therapies. Will new applications (on top of the 57) also be considered for the selection of 10 promising therapeutics?

Thanks in advance for your response and do let us know if you require any additional information.

With kind regards,

[Name]

[Email]

---

From: [Name]
Sent: Monday, 24 May 2021 11:19
To: [Name]@ec.europa.eu
Subject: European Commission’s COVID-19 therapeutics strategy

Dear [Name],

I hope all is well.

I am contacting you in name of one of our clients, regarding the European Commission’s COVID-19 therapeutics strategy.

We have a couple of questions on this, seeing as we were not able to find any additional information regarding certain procedures. We were wondering if you could provide us with some more information on the following:

- What are the selection criteria for scanning/mapping candidate therapeutics? Are there ways of applying or making oneself known for this procedure?
• The current timeline notes the selection of 5 promising candidate therapeutics by June. Are these specific potential therapies or categories of therapeutics (anti-body treatment, anticoagulation drugs, etc.)?
• If there are ways for potentially promising therapeutics to make themselves known to the European Commission, through what mechanism/procedure should this happen?

Do let us know if you require any additional information. We look forward to your response.

With high regards,

D: +32

M: +32

@hkstrategies.com